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The eﬀort to develop a tuberculosis (TB) vaccine more eﬀective than the widely used Bacille Calmette-Gu´ erin (BCG) has led to the
development of two novel fusion protein subunit vaccines: Ag85B-ESAT-6 and Ag85B-TB10.4. Studies of these vaccines in animal
models have revealed their ability to generate protective immune responses. Yet, previous work on TB fusion subunit vaccine
candidate, Mtb72f, has suggested that genetic diversity among M. tuberculosis strains may compromise vaccine eﬃcacy. In this
study, we sequenced the esxA, esxH, and fbpB genes of M. tuberculosis encoding ESAT-6, TB10.4, and Ag85B proteins, respectively,
in a sample of 88 clinical isolates representing 57 strains from Ark, USA, and 31 strains from Turkey, to assess the genetic diversity
of the two vaccine candidates. We found no DNA polymorphism in esxA and esxH genes in the study sample and only one
synonymous single nucleotide change (C to A) in fbpB gene among 39 (44.3%) of the 88 strains sequenced. These data suggest
that it is unlikely that the eﬃcacy of Ag85B-ESAT-6 and Ag85B-TB10.4 vaccines will be aﬀected by the genetic diversity of M.
tuberculosis population. Future studies should include a broader pool of M. tuberculosis strains to validate the current conclusion.
1.Introduction
The need for an improved vaccine against tuberculosis (TB)
has never been more urgent. One in three people today are
infected with Mycobacterium tuberculosis, the causative agent
of TB, and worldwide approximately three million people
die from TB annually. The currently available TB vaccine,
Bacille Calmette-Gu´ erin (BCG), has failed to consistently
protectagainstthemostcontagiousformofthedisease,adult
pulmonary TB, despite its widespread use [1–4]. Developing
an e wv a c c i n e ,wh i c hm a ys e rv ea sab o o s t e ro rar e p l a c e m e n t
for BCG, is of critical importance in the ﬁght against
worldwide TB-related morbidity and mortality [4, 5].
Of the various vaccine candidates proposed, fusion
subunit vaccines have received considerable attention in
the recent literature, especially those composed of antigenic
proteins ESAT-6, Ag85B, and TB10.4 [3–8]. It appears that
the multiple epitopes that fusion subunit vaccines oﬀer
makes them more eﬀective than single-peptide vaccines
in interacting with the complexity of the host immune
response against TB and the genetic restriction imposed
by major histocompatibility complex molecules [3, 9]. Two
fusion subunit vaccines, Ag85B-ESAT-6 and Ag85B-TB10.4,
which are the focus of the present study, have been found
to induce protective cell-mediated immunity in animal
models [3, 6, 7, 9, 10]. Ag85B-ESAT-6 is currently in
expanded Phase I studies in which the vaccine is tested in
BCG-vaccinated, latently infected, and individuals from TB
endemic regions [4]. As these candidates move forward in or
towardclinicaltrials,itwillbecriticallyimportanttoevaluate
their protective potential as global vaccines via bioinformatic
approaches built upon the comparative genomics of the
pathogen population and the immunomics of the host
population.2 Journal of Biomedicine and Biotechnology
Bioinformatics approaches are invaluable to the develop-
ment of eﬀective vaccine candidates. Comparative genomics
of the pathogen population, for instance, allows vaccine
candidates that are potentially ineﬀective due to genetic
diversity of the pathogen population to be discredited before
they reach the costly stages of clinical trials. In other words,
bioinformatic approaches can provide information based
on which a rational selection of clinical trial sites can
be made. As for subunit vaccines, comparative genomics
can help analyze whether antigenic targets are conserved
among infectious strains of an organism in order to ensure
their protective eﬃcacy across diverse pathogen populations
circulating in diﬀerent geographic region [8].
Although previous studies have suggested that M. tuber-
culosis has a relatively stable genome in comparison with
other bacteria [11, 12], recent genomic studies have revealed
biologically signiﬁcant variation among clinical strains [13].
Hebert and colleagues, for instance, revealed considerable
genetic variation in the PPE18 gene of M. tuberculosis,
with important implications for the ability of the Mtb72f
vaccine candidate to provoke protective immunity against
diverse populations of M. tuberculosis [14]. Furthermore, the
interaction of the genetic variation of the PPE18 component
of Mtb72f with the allelic variation of human MHC-II
DRB1 proteins negatively aﬀects vaccine epitope binding
to DRB1 proteins [15]. Taken in the context of vaccine
development, revelations like these are crucial to the survival
of vaccine candidates as potential clinical vaccines. A similar
comparative genomics study on Ag85B-ESAT-6 and Ag85B-
TB10.4 subunit vaccines may provide useful information for
predicting the protective eﬃcacy of these candidates in the
pre- or early stages of their clinical evaluation.
Little information has been documented on the genetic
variation of the genes encoding for ESAT-6, Ag85B, and
TB10.4 proteins. If any of these three genes is highly variable,
the protective eﬃcacy of Ag85B-ESAT-6 and Ag85B-TB10.4
subunit vaccines might be compromised on the global
stage. To further investigate the ability of these two-vaccine
candidates in recognizing naturally occurring M. tuberculosis
strains, we investigate the genetic diversity of the esxA,
esxH,a n dfbpB genes of M. tuberculosis that encode for the
components of the two new subunit vaccines in a sample
of 88 M. tuberculosis strains collected from Turkey and
Arkansas, USA.
2.MaterialsandMethods
2.1. M. tuberculosis Isolates. The clinical strains used in the
present study are from Ark, USA, and Turkey. Following the
work of Herbert and colleagues, the isolates were selected to
represent diﬀerent geographical regions, including Arkansas
and Malatya, Turkey, to assess the impact of regional genetic
variability on the two subunit vaccine candidates [14].
Each of the selected isolates represents a diﬀerent strain of
M. tuberculosis with a distinct IS6110 restriction fragment
polymorphism (RFLP) pattern with more than ﬁve bands or
a distinct combination of a common IS6110 RFLP pattern
with ﬁve or less bands and a unique spoligo typing pattern
(Table 1). The rationale for including isolates from two
geographical regions was to discern the potential impact of
genetic variation on future vaccination with Ag85B-ESAT-6
and Ag85B-TB10.4 in separate populations.
Our initial intent was to analyze the same set of clinical
isolates (n = 225) used by Hebert and colleagues in
their work on PPE18 and pepA [14]. However, after initial
sequencing of a randomly selected subset (n = 41) of
the 225 isolates revealed no genetic variation in the ESAT-
6, TB10.4, and Ag85B genes, we selected only 47 of the
remaining 84 isolates that had previously shown variation
in the PPE18 gene (n = 47) for the current study. This
decision was made with the consideration of cost-eﬀective
lab procedure, reasoning that local genetic variations would
be indicative of broader genomic variability. The 88 study
isolates represent 57 diﬀerent strains from Ark, USA, and
31 distinct strains from Turkey. The 88 study isolates
shared 49 diﬀerent spoligotypes that represent 47 diﬀerent
spoligo international types, as determined by using the
query tool of the fourth international spoligotyping database
(SpolDB4) [16]. The present sample represents 80 of 84
strains (95.2%) that showed PPE18 variation in Hebert’s
study.
2.2. PCR of esxA, esxH, and fbpB Genes. The three genes
under study were ampliﬁed using Invitrogen Platinum
Taq PCRx Polymerase kit (Invitrogen, Carlsbad, CA) with
primers published previously [17]. The primers used for
esxA, encoding the ESAT-6 protein were esxA-F (5 -GCA-
ATCCGGCGGCTCCACCAG-3 ) located 533bp upstream
of the esxA gene and esxA-R (5 -TCGGCCGCCATGACA-
ACCTCTC-3 ) located 124bp downstream from the end
of the esxA gene. The primers used for esxH, encoding
the TB10.4 protein were esxH-F (5 -GAGAGGGGGAGG-
CGACGGCTTACC-3 ) located 411bp upstream of the esxH
gene, and esxH-R (5 -TCCCCGCCCCAATGGTTTCAGC-
3 ) located 86bp downstream from the end of the esxH gene.
Finally, the primers used for fbpB, encoding Ag85B pro-
teinwerefbpB-F2(5 -ACTCGGCTAACTGGCTGGTGC-3 )
located 217 bp upstream of the fbpB gene, and fbpB-R (5 -
CATACCGCCATACCGTTTGTGAGC-3 ) located 164bp
downstream from the end of the fpbB gene. The inclusion
of the regions ﬂanking the esxA, esxH,a n dfbpB genes
allowed further conﬁrmation that the PCR products were
speciﬁc. The positive control in all the PCR reactions was M.
tuberculosis H37Rv, and the negative control was PCR-grade
water. The 50µL PCR reaction mixture used was composed
of 5µLo f1 0× PCRx ampliﬁcation buﬀer, 1.5µLo f5 0m M
MgSO4,1 µL of 10mM deoxyribonucleoside triphosphate
mixture, 20pmol of each primer in 1µL, 0.5µLo fI n vi t r o g e n
Platinum Taq polymerase mixture, 4µLo faD N As o l u t i o n
containing 50ng of DNA template, and 40µLo fP C R - g r a d e
water. The thermocycling program used for all genes was one
cycle at 94
◦C for 1 minute; 30 cycles of 94
◦C for 30 seconds,
62
◦C for 30 seconds, and 72
◦C for 2.5 minutes; and a ﬁnal
cycle of 72
◦C for 10 minutes. The sizes of the PCR products
were veriﬁed by 1.0% (wt/vol) agarose gel electrophoresis in
1 ×Tris-borate-EDTA buﬀer.Journal of Biomedicine and Biotechnology 3
Table 1: Genotyping data of the 88 study isolates of M. tuberculosis that were originated from Arkansas, USA, and Turkey.
Isolate
no.∗
IS6110
Copy
no.
IS6110
RFLP
Pattern 
Spoligotype Isolate
no.∗
IS6110
Copy
no.
IS6110
RFLP
Pattern 
Spoligotype
SA143 14 01046 000000000003771 SA208 03 00370 700036777760471
SA033 18 01063 000000000003771 SA738 07 05660 777777744720771
SA604 18 04495 000000000003771 SA204 10 00636 074377607760700
SA327 21 00237 000000000003771 SA565 09 01321 377737774020731
SA374 22 02623 000000000003771 SA710 17 02661 737377677760771
SA413 22 02660 000000000003771 SA221 01 00129 774377777413771
SA193 14 00638 677737607760771 SA253 14 00619 776377613760771
SA759 12 05774 677777477413771 SA052 03 00403 777776777560601
SA639 15 04804 703777740003771 SA333 04 01658 777776777560601
SA085 11 01336 776177607760771 SA597 07 04433 777776777760761
SA557 11 04222 776177607760771 SA286 08 01330 777777000020771
SA378 09 02620 777777770000000 SA198 03 00370 777777777613771
SA652 08 01646 777777774020771 SA173 19 00401 Not Available
SA053 11 00499 777777774020771 TK035 09 TK035 000000004020771
SA475 05 04430 777777777720771 TK036 08 TK036 000000007760771
SA010 09 00472 777777777720771 ZD073 15 ZD073 703777740003031
SA637 10 04802 777777777720771 TK013 03 TK013 777777404760771
SA213 13 00640 777777777720771 TK091 03 TK091 777777404760771
SA364 13 00807 777777777720771 TK110 08 TK110 777777740460771
SA025 11 00325 777777777760731 ZD039 08 ZD039 777777774020771
SA310 10 00315 776177607760771 ZD056 09 ZD056 777777774020771
SA285 06 01329 777777777760771 ZD061 08 ZD061 777777777720771
SA169 09 00326 777777777760771 ZD063 08 ZD063 777777777720771
SA120 12 00372 777777777760771 ZD034 09 ZD034 777777777720771
SA102 12 00538 777777777760771 TK086 10 TK086 777777777720771
SA471 14 06474 777777777760771 ZD013 10 ZD013 777777777720771
SA131 15 00627 777777777760771 ZD020 11 ZD020 777777777720771
SA157 06 00314 777777557760771 ZD071 11 ZD071 777777777720771
SA030 13 00570 777777607560771 TK065 05 TK065 777777777760771
SA706 10 05458 777777777760471 TK103 08 TK103 777777777760771
SA111 02 00016 777776777760771 TK095 09 TK095 777777777760771
SA352 03 00064 777776777760771 ZD062 09 ZD062 777777777760771
SA019 04 00432 777776777760771 TK030 10 TK030 777777777760771
SA170 06 00327 777776777760771 TK105 11 TK105 777777777760771
SA341 03 00694 777776777760601 ZD093 13 ZD093 757777777760771
SA020 05 00392 777776777760601 TK003 06 TK003 037637777760771
SA596 07 04432 777776777760601 ZD041 06 ZD041 777777764020731
SA526 01 00195 777777776413771 ZD031 09 ZD031 717777777760771
SA162 04 00319 700076777760700 ZD024 09 ZD024 770000770000000
SA778 08 06019 376177607760771 TK007 08 TK007 777767777760671
SA038 11 00496 777777777320771 TK016 07 TK016 037227760160771
SA512 12 00832 776377770760771 TK011 08 TK011 700377777760771
SA189 13 00598 777763777760771 TK112 09 TK112 777207777777661
SA430 01 00129 763777777413771 TK097 05 TK097 Not Available
∗Isolate numbers starting with SA refer to strains from Arkansas, USA. Isolate numbers starting with ZD or TK refer to strains from Turkey.
 The IS6110 RFLP patterns of the Arkansas strains were indicated using the national designations assigned by the National Tuberculosis Genotyping and
Sentinel Surveillance Network Program of the Centers for Disease Control and Prevention. The IS6110 RFLP patterns of the Turkish strains were designated
using the isolate number in which a given IS6110 RFLP pattern was observed for the ﬁrst time.4 Journal of Biomedicine and Biotechnology
2.3. Automated DNA Sequencing. PCR products were
sequenced to identify any insertions/deletions or single
nucleotide polymorphisms (SNPs) in the esxA, esxH,a n d
fbpB genes in the selected isolates. PCR products were
puriﬁed using Invitrogen PureLink PCR Puriﬁcation Kit,
according to manufacturer instructions (Invitrogen, Carls-
bad, CA). DNA sequencing was performed with Applied
Biosystems DNA sequencers 3700 and 3730 at the University
of Michigan Sequencing Core, using the same primers
that were used for the PCR of the three genes. The
sequences of esxA, esxH,a n dfbpB of the study strains
were compared to those of M. tuberculosis laboratory refer-
ence strain H37Rv (GenBank accession number BX842575)
using the BLAST and BLAST2 nucleotide sequence align-
ment program of the National Center for Biotechnology
Information (http://www.ncbi.nlm.nih.gov/BLAST) and the
Sequencher 4.9 DNA Sequence Assembly software (Demo
version) of Gene Codes Corporation (www.genecodes.com).
Primary DNA transcripts were translated to amino acid
sequences using the in silico simulation of molecular
biology experiment of the University of Basque Country
(http://insilico.ehu.es/).
3. Results andDiscussion
3.1. Genetic Diversity of esxA, esxH, and fbpB and Cor-
responding Amino Acid Sequences. Among the 88 strains
investigated, genetic analysis of esxA and esxH in this study
revealednonucleotidepolymorphismsinthegenesencoding
for ESAT-6 and TB10.4 proteins. Of the 88 strains, 38
(43.2%) belong to principal genetic group 1, 29 (33.0%)
belong to principal genetic group 2, and 21 (23.9%) belong
to principal genetic group 3. The principle genetic groups
were deﬁned by SNPs in the katG and gyrA genes as
described previously by Sreevatsan and colleagues [12].
Unlike the study by Herbert et al., where genetic group 1
strains were found to have the highest frequency of DNA
polymorphisms in the PPE18 protein, a component of the
Mtb72f vaccine [14], strains in all of the three principal
genetic groups showed no DNA variations in both esxA
and esxH. This observation suggests that these gene regions
mightbeconservedamongM.tuberculosisstrainsofdiﬀerent
geographic origins and among diﬀerent genetic groups of
the pathogen. In fact, Gey Van Pittius and colleagues have
recentlypositedinterspeciesconservationoftheESAT-6gene
regionaspartofanovelGram-positive secretionsystemwith
distant homologues in Bacillus subtilis, Bacillus anthracis,
Staphylococcus aureus, and Clostridium acetobutylicum [18].
The analysis of fbpB, the gene encoding for Ag85B
revealed only one synonymous C to A SNP, located at
position 714bp of the gene sequence, among 39 (44.3%)
of the 88 strains sequenced. Double strand sequencing was
conducted on the 39 isolates to conﬁrm the existence of this
SNP. Although this SNP had no eﬀect on the amino acid
sequence of the peptide when translated, it is indicative of
an allelic variation in the M. tuberculosis gene pool. Of the
39 strains, 15 (17.0%) belong to principal genetic group
1, 11 (12.5%) belong to principal genetic group 2, and 13
(14.7%) belong to principal genetic group 3. Furthermore,
the SNP was not found to be associated with any speciﬁc
geographic origin of the study strains, suggesting that this
particular nucleotide polymorphism is of ancestral origin.
These data suggest that M. tuberculosis Ag85B antigen is
highly conserved in, at least, certain populations of M.
tuberculosis clinical strains.
3.2. Implications for Immunization. TB remains one of the
deadliestinfectiousdiseasesofourtimes.Despitewidespread
use of the BCG vaccine, the disease continues to claim 2-3
million lives per year. The need for a new vaccine has never
been more urgent. In order to gain insight into the eﬃcacy of
two new vaccine candidates, two fusion proteins combining
Ag85B and ESAT-6, and Ag85B and TB10.4 [6, 9, 10],
respectively, the gene regions encoding for ESAT-6, TB10.4,
and Ag85B proteins were analyzed for their variability.
Experiments involving these two candidates have revealed
them to be eﬀective in generating protective immunity in
animal models [6, 9, 10].
Yet, while animal models have played an important role
in the development of new TB vaccines so far, they are
not always representative of the internal human biological
environment. As Flynn noted earlier, animportant drawback
of the murine model is that the pathology of pulmonary
TB in mice is quite diﬀe r e n tf r o mt h a ti nh u m a n s[ 19].
Speciﬁcally, the heterogeneity of granuloma types observed
in the human host is not displayed in the mouse lung [19].
Similar diﬃculties arise when using other animal models.
In the case of bovine infection, the pathology of TB is
quite similar to human host response in granulomatous
reactions, but diﬀers with respect to cavitation [20]. Non-
human primate models also represent the human pathology
of TB quite well, but like cattle are limited by economic and
infrastructural factors [20].
Furthermore, current preclinical studies of new TB vac-
cines’ protection against M. tuberculosis infection in animal
modelsdonottakethepopulationdiversityofM.tuberculosis
into consideration. However, as Hebert and colleagues noted
previously [14], genetic diversity of M. tuberculosis genes can
befoundamongclinicalisolates,andsuchdiversitymayhave
important implications for the eﬃcacy of the new vaccines.
Thus, comparative genomics of the pathogen population
stands as an additional useful tool for pre-clinical evaluation
of new vaccines, providing information complementary to
those from current in vivo and in vitro studies. Given the
resource-demanding nature of clinical trials, comparative
genomics serves as a method for predicting the potential
protection of proposed vaccines candidates in the general
population. Hebert and colleagues’ work revealed that the
PPE18 protein, part of the Mtb72f subunit vaccine, was
quite variable among isolates collected from Turkey and
Arkansas [14]. Analyzing the variability of antigens targeted
bypotentialvaccinesinadiversesetofisolatesatthegenomic
level may indeed allow researchers to avoid developing a
vaccine that is only variably eﬀective like the current BCG.
The ﬁndings of such study can also inform the rational
selection of the study populations, with a consideration ofJournal of Biomedicine and Biotechnology 5
covering the diverse pathogen populations in clinical trials of
new vaccines.
Our observation that ESAT-6, TB10.4, and Ag85B pro-
teins were highly conserved in our study sample comprising
strains from two geographically distant regions and three
diﬀerent principal genetic groups suggest that it is unlikely
that the eﬃcacy of Ag85B-ESAT-6 and Ag85B-TB10.4 sub-
unit vaccines will be aﬀected by the genetic diversity of M.
tuberculosis population. Thus, the protective eﬃcacy of these
two novel vaccine candidates may have a wider reach than
Mtb72b vaccine, which contains a highly variable antigen
of M. tuberculosis [14]. However, our ﬁndings also indicate
the need for further bioinformatics research on the three
genes investigated and their speciﬁc interaction with the
host immune system. While highly conserved genes are
indicative of homologous protein antigens, they may also
suggest a lack of selective pressure by the host immune
system and thus a lack of recognition on behalf of the
host’s immune response. Previous examples of the inability
of animal models to accurately represent the human host
environment suggest that the degree to which the human
host system interacts with these important peptides remains
to be studied.
The goal of pre-clinical evaluation of these two vaccines
may be furthered by future studies that include a larger
sample of isolates from a greater range of geographic origins,
making the data even more representative of the diversity
of M. tuberculosis worldwide. The ﬁnding of this study that
esxA, esxH,a n dfbpB were conserved across 88 clinical strains
from Arkansas and Turkey does not conﬁrm that they are
conserved globally. Including a larger and more genetically
diverse sample of isolates would address the two primary
limitations of this study—the number and diversity of the
isolates used.
Another factor that must be taken into account is the
potential impact that host diversity may have on the global
coverage of these two new TB vaccines. This study looked at
the diversity of pathogen genes coding for vaccine proteins,
but even uniformly conserved proteins may fail to induce
protective immunity if host diversity impedes their ability
to eﬀectively bind eﬀector immune cells. McNamara and
colleagues provide an eloquent, bioinformatic approach
to studying the impact that host diversity may have on
Mtb27f vaccine coverage by analyzing the allelic variation
of human class II MHC DRB1 proteins and its impact on
proper vaccine epitope binding [15]. A similar study on
Ag85B-ESAT-6 and Ag85B-TB10.4 may provide insightful
information on host diversity and its impact on the coverage
of these vaccines.
With these future directions in mind, the results of
the present study represent an important ﬁrst step in the
pre-clinical bioinformatic assessment of Ag85B-ESAT-6 and
Ag85B-TB10.4 vaccine candidates, and the impact that
genetic diversity among their respective antigenic protein
targets has on their potential success as global vaccines. The
ﬁnding that esxA, esxB, and fbpB genes are highly conserved
in two distinct populations suggests that Ag85B-ESAT-6
and Ag85B-TB10.4 vaccine candidates may be eﬀective in
geographically distinct areas of the world.
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